Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins.
Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.
van Drunen Littel-van den Hurk
S
S
Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
Gifford
G A
GA
Babiuk
L A
LA
D000818:Animals; D000917:Antibody Formation; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D000939:Epitopes / Q000276:immunology*; D007242:Herpesvirus 1, Bovine / Q000276:immunology; D007241:Infectious Bovine Rhinotracheitis / Q000276:immunology / Q000517:prevention & control*; D014764:Viral Proteins / Q000276:immunology* / Q000494:pharmacology; D014765:Viral Vaccines / Q000494:pharmacology
D000939:Epitopes; D014764:Viral Proteins; D014765:Viral Vaccines; C046998:bovine herpesvirus type-1 glycoproteins